Abemaciclib
- Generic Name
- Abemaciclib
- Brand Names
- Verzenio, Verzenios
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32F2N8
- CAS Number
- 1231929-97-7
- Unique Ingredient Identifier
- 60UAB198HK
- Background
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative a...
- Indication
适应症为:⑴单药治疗接受过内分泌疗法和化疗后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑵或联合氟维司群，二线治疗接受过内分泌疗法后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑶联合芳香酶抑制剂作为 ER+/HER2-绝经后女性晚期或转移性乳腺癌的初始内分泌疗法。
- Associated Conditions
- HR+, HER2-, Advanced Breast Cancer, Early Hormone Receptor Positive, HER2/Neu Negative Node Positive Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10
- Registration Number
- NCT05999968
- Locations
- 🇪🇸
Hospital General Universitario Gregorio Marañon, Madrid, Madrid, Comunidad De, Spain
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
🇩🇪Studienpraxis Urologie, Nürtingen, Baden-Württemberg, Germany
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5500
- Registration Number
- NCT05952557
- Locations
- 🇬🇧
Research Site, Whitchurch, United Kingdom
Abemaciclib in Newly Diagnosed Meningioma Patients
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Nader Sanai
- Target Recruit Count
- 72
- Registration Number
- NCT05940493
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 135
- Registration Number
- NCT05933395
- Locations
- 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 766
- Registration Number
- NCT05891093
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangdong, Guangzhou, China
🇨🇳Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 100
- Registration Number
- NCT05872204
- Locations
- 🇫🇷
Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, Île-de-France, France
🇳🇱Erasmus Medical Center Rotterdam, Rotterdam, South Holland, Netherlands
🇫🇷Centre Leon Berard, Lyon, Métropole De Lyon, France
Study of AVZO-021 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Avenzo Therapeutics, Inc.
- Target Recruit Count
- 430
- Registration Number
- NCT05867251
- Locations
- 🇺🇸
NEXT Virginia, Fairfax, Virginia, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sidney Kimmel Cancer Center (SKCC) at Jefferson Health, Philadelphia, Pennsylvania, United States
Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.
- Conditions
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 136
- Registration Number
- NCT05789771
- Locations
- 🇷🇺
Russian Society of Clinical Oncology, Moscow, Russian Federation
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
- Conditions
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Glenn J. Hanna
- Target Recruit Count
- 10
- Registration Number
- NCT05774899
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05766410
- Locations
- 🇨🇳
Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan
🇨🇳Department of Oncology,National Taiwan University Hospital, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.